Montag & Associates’s Alkermes ALKS Stock Holding History

Montag & Associates’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11	Closed	-$330	–	955
2025 Q3	$330	Buy	+11	New	+$310	﹤0.01%	1106

Other funds holding ALKS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Montag & Associates's ALKS Position: Q4 2025 in Review

Montag & Associates sold out of Alkermes (ALKS) in Q4 2025, closing a stake of 11 shares — an estimated $330 sold.

Montag & Associates first reported a position in ALKS in Q3 2025 and held it in 1 quarter. The position peaked at $330 in Q3 2025. 366 funds tracked by Wall St. Rank hold ALKS as of Q4 2025.

Montag & Associates reported no remaining Alkermes position as of Q4 2025 after selling out during the quarter.
Montag & Associates sold 11 Alkermes shares in Q4 2025, an estimated $330.
Montag & Associates first reported a position in Alkermes in Q3 2025 and held it in 1 quarter.
Montag & Associates's Alkermes position peaked at $330 in Q3 2025.
366 funds tracked by Wall St. Rank held Alkermes as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.